Sudeep Pharma reported a strong Q1 FY27 with revenue rising 26.7% to ₹158.3 crore and net profit up 29.7% to ₹40.6 crore. The company sees growth in its Pharma, Food, and Nutrition segment and progresses on its battery materials project.
Sudeep Pharma Posts Strong Q1 FY27 Results
Revenue from operations stood at ₹158.3 crore, up 26.7% from ₹124.9 crore in Q1 FY26. Profit after tax surged 29.7% to ₹40.6 crore from ₹31.3 crore year-on-year. Reader Takeaway: Robust revenue growth and profit increase offset raw material price hikes. ## What just happened Sudeep Pharma Ltd. announced its financial results for the first quarter of FY27 (ending June 30, 2026). The company reported a significant 26.7% increase in revenue from operations, reaching ₹158.3 crore. Profit after tax (PAT) also saw a healthy jump of 29.7%, closing at ₹40.6 crore for the quarter. EBITDA grew by 25.1% to ₹54.9 crore. ## Why this matters The strong performance indicates Sudeep Pharma's ability to navigate market challenges and capitalize on demand. The growth in profitability, despite rising input costs like phosphoric acid, signals efficient cost management and pricing power. Progress on strategic initiatives, such as the battery materials project, adds a layer of future growth potential for investors. ## The backstory In the previous fiscal year (FY26), Sudeep Pharma focused on consolidating its market position and expanding its product portfolio. The company has been strategically investing in new business segments like battery materials while maintaining strength in its core pharmaceutical, food, and nutrition divisions. ## What changes now The company is set to benefit from its growth drivers, including the expanding Pharma, Food, and Nutrition segment, which contributed 69% of Q1 revenue. The normalization of operations in the Specialty Ingredients segment after LPG supply issues and continued efforts to improve its European subsidiary's performance are key focus areas. The battery materials project is progressing, with Phase 1 commissioning targeted for April 2027. ## Risks to watch Sudeep Pharma flagged a significant increase in phosphoric acid prices, up by approximately 50% during the quarter. The company is focused on passing these costs to customers to protect margins. The European subsidiary (NSS) continues to face headwinds from high energy costs and an industrial slowdown, with recovery expected to be gradual. ## Peer comparison While specific peer data for Q1 FY27 is not detailed in the filing, Sudeep Pharma's broad-based revenue growth of 26.7% suggests a strong performance relative to the broader chemical and pharmaceutical ingredients sector, which has faced margin pressures. ## Context metrics (time-bound) * Revenue from operations: ₹158.3 crore (Q1 FY27) vs ₹124.9 crore (Q1 FY26) - +26.7% * Profit after tax: ₹40.6 crore (Q1 FY27) vs ₹31.3 crore (Q1 FY26) - +29.7% * EBITDA: ₹54.9 crore (Q1 FY27) vs ₹43.9 crore (Q1 FY26) - +25.1% * Phosphoric acid price increase: ~50% during Q1 FY27 ## What to track next Investors will be keen to monitor the commissioning of the new greenfield facility from Q3 FY27, the scale-up of battery material operations, and the company's ability to manage raw material price volatility and protect margins. Progress in the GLP-1 weight management category and clinical nutrition segments will also be key indicators.
